| Literature DB >> 31660922 |
Tewodros H Gebremariam1, Charles B Sherman2, Neil W Schluger3,4.
Abstract
BACKGROUND: Patient awareness of asthma severity is important for optimal asthma management. However, there is often a discrepancy between physician assessment of asthma control based on guidelines and patient discernment of control. We compared physician and patient perception of asthma control in a clinic population seen at a tertiary hospital in Addis Ababa, Ethiopia.Entities:
Keywords: GINA symptom assessment tool; SABA overuse; Self-reported asthma control
Mesh:
Year: 2019 PMID: 31660922 PMCID: PMC6819349 DOI: 10.1186/s12890-019-0959-7
Source DB: PubMed Journal: BMC Pulm Med ISSN: 1471-2466 Impact factor: 3.317
Reported asthma symptoms in 182 patients seen in Chest Clinic at Tikur Anbessa Specialized Hospital
| Symptom | Frequency | Percent |
|---|---|---|
| Nighttime awakening due to asthma | 117 | 64.3 |
| Daytime symptoms (wheeze or dyspnea) more than twice per week | 105 | 57.7 |
| Activity limitations due to asthma | 52 | 28.6 |
Asthma medication use in182 subjects seen in Chest Clinic at Tikur Anbessa Specialized Hospital
| Type of medication | Frequency | Percent |
|---|---|---|
| Short acting beta agonist (SABA) | 173 | 95.1 |
| Inhaled corticosteroids (ICS) | 105 | 57.7 |
| Consistent ICS use | 95 | 52.2 |
| Combination ICS and long acting beta agonist (LABA) | 19 | 10.4 |
| Oral steroids | 25 | 13.7 |
Frequency of patients with poor perception of asthma control
| Asthma control by Physician assessment (based on GINA) | |||
|---|---|---|---|
| Well Controlled ( | Partly controlled/uncontrolled ( | ||
| Patient Perception of asthma | Good Control | 42 (95.5%) | 109 (79%) |
| Poor Control | 2 (4.5%) | 29 (21%) | |
GINA Global Initiative for Asthma management and prevention
Demographic characteristics of patients grouped as self-reported good asthma control or self-perceived poor control
| Variable | Self-reported good asthma control ( | Self-perceived poor asthma control ( | Adjusted | OR | ||
|---|---|---|---|---|---|---|
| Age(yr), Mean(SD) | 51.6(12.4) | 52.3(10.55) | 0.76 | 0.31(0.05–4.03) | ||
| Female(%) | 106(70.2) | 18(58.1) | 0.19 | 0.59(0.27–1.30) | ||
| Duration of Asthma (yr), Mean(SD) | 19.6(11.6) | 18.2(17.5) | 0.57 | 0.57(0.35–6.42) | ||
| Level of education (%) | Illiterate | 37(24.5) | 12(38.7) | 0.11 | 1.95(0.86–4.38) | |
| Literate | 114(75.5) | 19(61.3) | ||||
| Smoking | Yes | 15(9.9) | 3(9.7) | 0.97 | 0.97 (0.26–3.58) | |
| No | 136(90.1) | 28(90.3) | ||||
| Biomass use for cooking | Yes | 51(34.9) | 15(51.7) | 0.09 | 0.34 | 0.62 (0.23–1.65) |
| No | 95(65.1) | 14(48.3) |
Clinical characteristics of patients grouped as self-reported good asthma control or self-perceived poor control
| Variable | Self-reported good asthma control ( | Self-perceived poor asthma control ( | Adjusted | OR | ||
|---|---|---|---|---|---|---|
| Day time symptom(>2x/wee) | Yes | 74(49) | 31(100) | 0.19 | 1.73(0.69–3.08) | |
| No | 77(51) | 0(0) | ||||
| Night awakening | Yes | 88(58.3) | 30(96.8) | 0.003 | 0.13 | 5.499(0.59–51.13) |
| No | 63(41.7) | 1(3.2) | ||||
| Use of reliever /SABA >2x/week | Yes | 87(57.6) | 28(90.3) | 0.002 | 0.076 | 4.29(0.86–21.45) |
| No | 64(42.4) | 3(9.7) | ||||
| Any Activity limitation | Yes | 58(38.4) | 24(77.4) | 0.000 | 0.045 | 3.05 (1.03–9.07) |
| No | 93(61.6) | 7 (22.6) | ||||
| Overall GINA control | Well controlled | 80(53) | 5(16.1) | 0.001 | 0.87 | 0.89 (0.21–3.66) |
| Partly controlled/Uncontrolled | 71(47) | 26(83.9) | ||||
| Exacerbation | Yes | 74(49) | 19(61.3) | 0.22 | 1.65 (0.75–3.63) | |
| No | 77(51) | 12 (38.7) | ||||
| Incorrect Inhaler Technique | Yes | 46(30.9) | 16(53.3) | 0.02 | 0.67 | 1.23 (0.48–3.12) |
| No | 103(69.1) | 14(46.7) | ||||
| Consistent ICS use | Yes | 85(56.3) | 10(32.3) | 0.002 | 0.02 | 4.63 (1.73–12.42) |
| No | 66(43.7) | 21(67.7) | ||||
| FVC | ≥ 80 | 44(55.7) | 11(64.7) | 0.497 | 0.69 (0.23–2.04) | |
| < 80 | 35(44.3) | 6(35.3) | ||||
| FEV1 | ≥ 80 | 19(24.1) | 5(29.4) | 0.64 | 0.76 (0.24–2.43) | |
| < 80 | 60(75.9) | 12(70.6) |
SABA Short acting beta agonist, GINA Global Initiative for Asthma management and prevention, ICS Inhaled corticosteroid, FVC Forced vital capacity, FEV1 Forced Expiratory volume in the first second